Nektar Therapeutics (NKTR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.…

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript…

Nektar Therapeutics NASDAQ: NKTR said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia areata study in December,…

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to a loss of $1.85 per share a year ago.…

SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments i…

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma Conference Format: …

CenterBook Partners LP bought a new position in Nektar Therapeutics (NASDAQ: NKTR) during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,346 shar…

NKTR's rezpegaldesleukin is now in phase 3 trials in atopic dermatitis, but there is additional data from the company's phase 2b REZOLVE-AD trial expected in Q1'27. The market focus has shifting back to atopic dermatitis…

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-b…

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified …

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Maze Therapeutics (NASDAQ: MAZE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses ba…

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.…

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price gapped down prior to trading on Thursday. The stock had previously closed at $60.54, but opened at $55.41. Nektar Therapeutics shares last traded at $50.…

Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reaction…

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript…

Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia a…

Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.…

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.…

Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism In alopecia area…

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen ratings firms that are covering the company, Marketbeat reports. One equities research anal…

Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics …

New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata Company to host conference call with investors and analysts on Octo…

SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualifi…

SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified s…

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.
Quiet tape today.

